Abstract
Immune checkpoints inhibitors (ICI) targeting CTLA-4 and PD-1 have achieved unprecedented results in advanced melanoma patients. Mechanisms of resistance are not fully understood and predictive biomarkers of response are to be identified. TNF is a pleiotropic cytokine whose role in cancer can be detrimental and TNF blockade potentiates ICI efficacy in preclinical models.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
